MA53868A - Composés agonistes du récepteur bêta des hormones thyroïdiennes - Google Patents
Composés agonistes du récepteur bêta des hormones thyroïdiennesInfo
- Publication number
- MA53868A MA53868A MA053868A MA53868A MA53868A MA 53868 A MA53868 A MA 53868A MA 053868 A MA053868 A MA 053868A MA 53868 A MA53868 A MA 53868A MA 53868 A MA53868 A MA 53868A
- Authority
- MA
- Morocco
- Prior art keywords
- receptor agonist
- thyroid hormone
- beta receptor
- agonist compounds
- hormone beta
- Prior art date
Links
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 title 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000005495 thyroid hormone Substances 0.000 title 1
- 229940036555 thyroid hormone Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745195P | 2018-10-12 | 2018-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53868A true MA53868A (fr) | 2021-08-18 |
Family
ID=70161488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053868A MA53868A (fr) | 2018-10-12 | 2019-10-10 | Composés agonistes du récepteur bêta des hormones thyroïdiennes |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11203587B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3863635A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7595004B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112839655B (cg-RX-API-DMAC7.html) |
| AR (1) | AR116694A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019357618B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA53868A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI884745B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020077123A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN113278013B (zh) * | 2020-02-20 | 2022-09-23 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
| WO2021244582A1 (zh) * | 2020-06-02 | 2021-12-09 | 成都康弘药业集团股份有限公司 | 新型甲状腺激素β受体激动剂 |
| WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
| CN112645936B (zh) * | 2020-12-17 | 2022-03-01 | 山东第一医科大学(山东省医学科学院) | 取代的哒嗪酮类化合物及其用途 |
| JP2024510935A (ja) * | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| DE60020786T2 (de) | 1999-09-30 | 2006-03-23 | Pfizer Products Inc., Groton | 6-Azauracilderivate als Liganden der Thyroidrezeptoren |
| CA2473162A1 (en) | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (fr) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| ATE480524T1 (de) * | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| KR101396606B1 (ko) | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EA023521B1 (ru) * | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN107074823B (zh) * | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| CN109574995B (zh) | 2018-01-23 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| WO2020041741A1 (en) | 2018-08-24 | 2020-02-27 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN119552152A (zh) | 2018-10-12 | 2025-03-04 | 益方生物科技(上海)股份有限公司 | 甲状腺激素受体激动剂 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| CN119431265A (zh) | 2019-02-21 | 2025-02-14 | 南京瑞捷医药科技有限公司 | 一种作为甲状腺激素受体激动剂的化合物 |
| WO2020239076A1 (zh) | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
-
2019
- 2019-10-09 TW TW113111231A patent/TWI884745B/zh active
- 2019-10-09 TW TW108136747A patent/TWI840423B/zh active
- 2019-10-10 AU AU2019357618A patent/AU2019357618B2/en active Active
- 2019-10-10 EP EP19870196.3A patent/EP3863635A4/en active Pending
- 2019-10-10 WO PCT/US2019/055689 patent/WO2020077123A1/en not_active Ceased
- 2019-10-10 JP JP2021519726A patent/JP7595004B2/ja active Active
- 2019-10-10 CN CN201980067301.7A patent/CN112839655B/zh active Active
- 2019-10-10 US US16/598,978 patent/US11203587B2/en active Active
- 2019-10-10 MA MA053868A patent/MA53868A/fr unknown
- 2019-10-11 AR ARP190102912A patent/AR116694A1/es unknown
-
2022
- 2022-06-30 US US17/855,672 patent/US20220348561A1/en not_active Abandoned
-
2024
- 2024-11-25 JP JP2024204381A patent/JP2025041602A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112839655B (zh) | 2025-11-25 |
| TW202430520A (zh) | 2024-08-01 |
| US20200115362A1 (en) | 2020-04-16 |
| EP3863635A1 (en) | 2021-08-18 |
| AU2019357618A1 (en) | 2021-04-29 |
| TW202027748A (zh) | 2020-08-01 |
| AR116694A1 (es) | 2021-06-02 |
| CN112839655A (zh) | 2021-05-25 |
| JP2022504620A (ja) | 2022-01-13 |
| JP2025041602A (ja) | 2025-03-26 |
| EP3863635A4 (en) | 2022-06-15 |
| AU2019357618B2 (en) | 2025-04-24 |
| WO2020077123A1 (en) | 2020-04-16 |
| TWI840423B (zh) | 2024-05-01 |
| US20220348561A1 (en) | 2022-11-03 |
| CA3114015A1 (en) | 2020-04-16 |
| TWI884745B (zh) | 2025-05-21 |
| JP7595004B2 (ja) | 2024-12-05 |
| US11203587B2 (en) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53448A (fr) | Composés agonistes des récepteurs bêta des hormones thyroïdiennes | |
| IL282076A (en) | Thyroid hormone receptor agonists | |
| EP4017875A4 (en) | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | |
| EP3863635A4 (en) | Thyroid hormone receptor beta agonist compounds | |
| EP4028008A4 (en) | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | |
| EP4069686A4 (en) | GPP-1 RECEPTOR AGONISTS | |
| IL283362A (en) | Thrβ receptor agonist compound and preparation method and use thereof | |
| EP4301357A4 (en) | Thyroid hormone receptor beta agonist compounds | |
| PT3807267T (pt) | Agonistas do recetor da hormona da tiroide e usos dos mesmos | |
| EP4036090A4 (en) | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | |
| MA52642A (fr) | Composés ciblant des récepteurs hormonaux nucléaires anticancéreux | |
| DK3820873T3 (da) | Selektive østrogenreceptornedbrydere | |
| DK3762380T3 (da) | Phenylpyrrolidinon-formylpeptid-2-receptoragonister | |
| DK3810201T3 (da) | GIP/GLP1-agonist-sammensætninger | |
| SG11202102162RA (en) | Anti-trem-2 agonist antibodies | |
| IL260318A (en) | A triple agonist for glucagon/glp-1/gip receptors | |
| IL304460A (en) | Estrogen receptor-modulating compounds | |
| PL3774862T3 (pl) | Nowe analogi glp-1 | |
| DK3820874T3 (da) | Selektive estrogenreceptornedbrydere | |
| IL280367A (en) | CD226 agonist antibodies | |
| EP3406264A4 (en) | COMPOSITION WITH GLP-1 RECEPTOR AGONISTS AND GLUCAGON RECEPTOR AGONIST AND USE THEREOF | |
| IL280199A (en) | Receptor for vista | |
| EP3720445A4 (en) | BETA 2 SELECTIVE ADRENERGIC RECEPTOR AGONISTS | |
| GB201816639D0 (en) | GLP-1 Receptor Antagonist | |
| IL277243A (en) | Inverted pyrazoles are FFA4/GPR120 receptor agonists |